Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 36,498 | 26,823 | 14,240 | 0 | 0 |
| Cost of Goods | 4,165 | 2,881 | 1,704 | 0 | N/A |
| Gross Profit | 32,333 | 23,942 | 12,536 | N/A | N/A |
| Operating Expenses | 458,235 | 416,310 | 402,287 | 378,418 | 335,916 |
| Operating Income | -425,737 | -391,487 | -389,047 | -378,418 | -335,916 |
| Other Income | 1,143,706 | 39,399 | 157,246 | 21,908 | 6,611 |
| Pre-tax Income | 717,969 | -352,088 | -231,801 | -356,510 | -329,305 |
| Income Tax | 44,244 | N/A | N/A | N/A | N/A |
| Net Income Continuous | 673,725 | -352,088 | -231,801 | -356,510 | -329,305 |
| Net Income Discontinuous | N/A | N/A | N/A | 1,961,225 | 1,935 |
| Net Income | $673,725 | $-352,088 | $-231,801 | $1,604,715 | $-327,370 |
| EPS Basic Total Ops | 11.86 | -6.33 | -4.23 | 26.55 | -4.74 |
| EPS Basic Continuous Ops | 11.86 | -6.33 | -4.23 | -5.90 | -4.77 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | 32.45 | 0.03 |
| EPS Diluted Total Ops | 11.64 | -6.33 | -4.23 | 26.55 | -4.74 |
| EPS Diluted Continuous Ops | 11.64 | -6.33 | -4.23 | -5.90 | -4.77 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | 32.45 | 0.03 |
| EPS Diluted Before Non-Recurring Items | -0.38 | -6.33 | -4.23 | -5.90 | -4.74 |
| EBITDA(a) | $-434,570 | $-389,915 | $-381,681 | $-362,229 | $-323,104 |